Stocktwits on MSN
Eli Lilly’s oral obesity drug passes maintenance test after Wegovy, Zepbound — Wall Street flags win for Viking Therapeutics
The company studied Orforglipron for weight maintenance over 52 weeks in patients who were on 72 weeks of popular injectable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback